Haixia Liu

393 Middle Huaxia Road
Pudong, 201210, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1).

Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1).

Journal: Bioorganic chemistry

Published: May 12, 2024

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers.

Journal: Cell chemical biology

Published: October 23, 2023

Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].

Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].

Journal: European journal of medicinal chemistry

Published: March 29, 2023

Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.

Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.

Journal: European journal of medicinal chemistry

Published: September 25, 2022

Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation.

Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation.

Journal: Chemical communications (Cambridge, England)

Published: August 22, 2022

Utilization of macrocyclic peptides to target protein-protein interactions in cancer.

Utilization of macrocyclic peptides to target protein-protein interactions in cancer.

Journal: Frontiers in oncology

Published: July 12, 2022

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

Journal: European journal of medicinal chemistry

Published: June 23, 2022

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation.

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation.

Journal: Cell chemical biology

Published: January 23, 2022

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Journal: Journal of medicinal chemistry

Published: June 17, 2021

CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma.

CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma.

Journal: Cancer science

Published: June 10, 2021

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.

Journal: European journal of medicinal chemistry

Published: April 02, 2021

Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.

Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.

Journal: European journal of medicinal chemistry

Published: December 23, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026